External Validation and Clinical Impact of the Barcelona Predictive Models for Detecting Significant Prostate Cancer in Prostate Biopsies in an Ibero-American Population
Authors:
- Nahuel PaesanoNPNahuel Paesano
- Juan CameanJCJuan Camean
- Maximiliano RingaMRMaximiliano Ringa
- Maximiliano López-SilvaMaximiliano López-Silva
- Guido KorenGKGuido Koren
- Tomás Eduardo OlmedoTOTomás Eduardo Olmedo
- Joaquín Ignacio GurovichJGJoaquín Ignacio Gurovich
- Edgar Iván Bravo-CastroEBEdgar Iván Bravo-Castro
- Violeta CataláVCVioleta Catalá
- Pablo ContrerasPCPablo Contreras
- Juan Justo-QuintasJJJuan Justo-Quintas
- José Miguel Pérez-RuizJPJosé Miguel Pérez-Ruiz
Open Access
Abstract
Objectives: To externally validate the Barcelona Predictive Models (BCN-PM 1 and 2) for detecting csPCa in an Ibero-American population. BCN-PM 1 was designed to reduce magnetic resonance imaging (MRI) use, whereas BCN-PM 2 aims to decrease unnecessary prostate biopsies. Methods: This prospective, multicenter study included 661 men with suspected PCa recruited in 2025 across three Ibero-American centers. All participants underwent MRI followed by targeted biopsies of lesions with the Prostate Imaging–Reporting and Data System (PI-RADS) ≥ 3, along with systematic biopsy. When PI-RADS lesions were p < 0.001). Decision curve analysis demonstrated a net benefit for both models compared with strategies of biopsy in all or no men. BCN-PM 2 showed greater net benefit than BCN-PM 1. At 95% sensitivity, BCN-PM 1 reduced MRI requests by 10.6%, while BCN-PM 2 avoided 19.4% of unnecessary biopsies. The sequential use of BCN-PM 1 and 2 resulted in a 10.6% reduction in MRI exams and a 23.1% reduction in biopsies, at the cost of missing 8.4% of csPCa cases. The performance of the biopsy improved from 53.7% to 64.0% (p < 0.001). Conclusions: BCN-PM1 and BCN-PM 2 were successfully validated in an Ibero-American population.Keywords
Funding Information
- Instituto de Salud Carlos III (PI23/03010)
This publication has 31 references indexed in Scilit:
- European validation of the Barcelona magnetic resonance predictive model for significant prostate cancer detection in prostate biopsiesBJUI Compass, 2026
- External validation of the barcelona magnetic resonance imaging predictive model for detecting significant prostate cancer including men receiving 5-alpha reductase inhibitorsWorld Journal of Urology, 2024
- Detection of Clinically Significant Prostate Cancer Using Targeted Biopsy with Four Cores Versus Target Saturation Biopsy with Nine Cores in Transperineal Prostate Fusion Biopsy: A Prospective Randomized TrialEuropean Urology Oncology, 2022
- Multi‐institutional analysis of clinical and imaging risk factors for detecting clinically significant prostate cancer in men with PI‐RADS 3 lesionsCancer, 2022
- A European Model for an Organised Risk-stratified Early Detection Programme for Prostate CancerEuropean Urology Oncology, 2021
- Screening for Prostate CancerJAMA, 2018
- 4Kscore Test, Prostate Cancer Prevention Trial-Risk Calculator y European Research Screening Prostate-Risk Calculator en la predicción del cáncer de próstata de alto grado; estudio preliminarActas Urológicas Españolas, 2016
- Standards of Reporting for MRI-targeted Biopsy Studies (START) of the Prostate: Recommendations from an International Working GroupEuropean Urology, 2013
- Prediction of Prostate Cancer Risk: The Role of Prostate Volume and Digital Rectal Examination in the ERSPC Risk CalculatorsEuropean Urology, 2012
- ESUR prostate MR guidelines 2012European Radiology, 2012